RxDoctor Payments Data

Wei Mi, MD

Neurology · Northridge, CANPI 1871601401

Payments from drug & device makers

$97,835in general payments, 2019–2025

Across 831 payments — averaging $117.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$57K
  • Eli Lilly$25K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • EMD Serono, Inc.$890
  • Amgen$851
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$51,21070%
  • Travel & lodging$7611%
  • Food & beverage$20,76328%
  • Education$3620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)203$57,337
Eli Lilly3$24,590
Novartis89$2,098
Teva Pharmaceuticals USA, Inc.63$1,638
EMD Serono, Inc.33$890
Amgen(2 entities)29$851
Eisai Inc.23$797
Biogen43$639
Biohaven Pharmaceuticals, Inc.17$525
Lilly USA, LLC22$474
Neurocrine Biosciences, Inc.17$473
SK Life Science, Inc.15$460
Jazz Pharmaceuticals Inc.9$444
Genentech USA, Inc.16$430
UCB, Inc.19$422
Acadia Pharmaceuticals Inc16$405
TG Therapeutics, Inc.14$367
MDD US Operations, LLC14$364
Bristol Myers Squibb10$350
Amneal Pharmaceuticals LLC16$324
Argenx US, Inc.9$304
E.r. Squibb & Sons, L.L.C.5$300
Sanofi11$263
CSL Behring10$236
Pfizer12$229
Sunovion Pharmaceuticals Inc.15$203
Lundbeck LLC10$197
Merz Pharmaceuticals, LLC6$187
Abbott4$182
Livanova USA, Inc.4$175
AstraZeneca(2 entities)3$145
Adamas Pharmaceuticals, Inc.7$132
Upsher-smith Laboratories LLC6$117
Otsuka America Pharmaceutical, Inc.5$97
Avanir Pharmaceuticals, Inc.4$89
Neurelis, Inc.4$77
Kyowa Kirin, Inc.3$71
Regeneron Healthcare Solutions, Inc.3$70
Akcea Therapeutics, Inc.1$68
Biohaven Pharmaceutical Holding Company Ltd.3$62
Supernus Pharmaceuticals, Inc.5$56
GRT US Holding, Inc.1$55
Promius Pharma LLC2$50
Catalyst Pharmaceuticals, Inc.1$50
Greenwich Biosciences, Inc.2$47
Impel Pharmaceuticals Inc.2$42
Assertio Therapeutics, Inc.2$41
Arbor Pharmaceuticals, Inc.2$39
Axonics, Inc.1$37
Harmony Biosciences LLC1$36
Merck2$34
Johnson & Johnson1$29
Progenics Pharmaceuticals, Inc.1$27
GE HealthCare1$24
Xeris Pharmaceuticals, Inc.1$23
Takeda Pharmaceuticals U.S.A., Inc.1$21
Saol Therapeutics Inc.1$20
Bausch Health US, LLC1$20
Ipsen Biopharmaceuticals, Inc1$19
Strongbridge US Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,835 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$172,044
Medicare patients
464
Services billed
9,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab42$372,307
NuplazidPimavanserin Tartrate32$206,443
TecfideraDimethyl Fumarate12$105,552
Aimovig AutoinjectorErenumab-Aooe106$86,823
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$83,639
CopaxoneGlatiramer Acetate14$80,323
Nurtec OdtRimegepant Sulfate35$60,901
NuedextaDextromethorphan Hbr/Quinidine28$43,707
VimpatLacosamide29$38,616
RytaryCarbidopa/Levodopa17$36,752
Emgality PenGalcanezumab-Gnlm26$27,184
UbrelvyUbrogepant17$26,669
Dalfampridine ErDalfampridine20$24,749
QuliptaAtogepant22$23,806
Emgality SyringeGalcanezumab-Gnlm21$23,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$405$206,44332 claims
BiogenTecfidera$639$105,55212 claims
CSL BehringPrivigen$236$83,63914 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,638$80,32314 claims
PfizerNurtec Odt, Eliquis, Dilantin$229$77,81888 claims
AbbVieUbrelvy, Qulipta, Botox, Linzess, Savella$57,337$75,80375 claims
UCB, Inc.Vimpat, Nayzilam$422$47,98040 claims
Avanir Pharmaceuticals, Inc.Nuedexta$89$43,70728 claims
Amneal Pharmaceuticals LLCRytary$324$36,75217 claims
AstraZenecaBrilinta$145$15,29612 claims
NovartisExelon$2,098$8,09712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Northridge

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →